Skip to main content

This medicinal product has been authorised under a 'conditional approval' scheme. This means that further evidence on this medicinal product is awaited.

Resources for you and your patients

View and download these resources to help you start and manage your patients on ZYNLONTA

Downloadable resources

Pharmacy Booklet - NEW LOGO
Pharmacy manual

Provides key information about ZYNLONTA for pharmacists and clinicians

Patient booklet NEW LOGO
Patient booklet

Provides information and support details for patients who have been initiated onto treatment with ZYNLONTA

Expert opinion videos

Expert Opinion Videos
Listen to expert opinions on ZYNLONTA

To view these videos, please register with Sobi Pro. Listen to Dr Adam Gibb, and Professor Graham Collins reflecting on their real world experience of ZYNLONTA and thoughts on changing treatment landscape in R/R DLBCL.

To view these videos, please register with Sobi Pro.

Real World Experience case studies

RWE video still 2026
RWE case study insight

Dr Dungarwalla and Professor Collins discuss factors involved in considering when to continue or stop treatment and the importance of specialist nurses in this decision.

To view these videos, please register with Sobi Pro.

BSH 2024 highlights

BSH video still 2026
Highlights collection

Watch short videos of views and thoughts from Dr Wendy Osborne and Professor Andy Davies at BSH 2024.

To view these videos, please register with Sobi Pro.

About ZYNLONTA

Contact

Need any further information?

  • Don’t hesitate to get in touch with any further questions you have

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Swedish Orphan Biovitrum Ltd by email at [email protected] or by calling +44 (0) 800 111 4754.

PP-30920
Other sites
expand_less